Enasidenib is a 1,3,5-triazine substituted with (2-hydroxy-2-methylpropyl)nitrilo at position 2, 6-(trifluoromethyl)pyridin-2-yl at position 4, and [2-(trifluoromethyl)pyridin-4-yl]nitrilo at position 6. It is an IDH2 inhibitor approved for treating adults with relapsed or refractory AML. It functions as an antineoplastic agent and EC 1.1.1.42 inhibitor. It is classified as an aminopyridine, organofluorine compound, secondary amino compound, tertiary alcohol, member of 1,3,5-triazines, and aromatic amine.
